Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1973 1
1975 1
1977 2
1978 3
1979 3
1981 1
1982 1
1984 1
1985 1
1986 1
1987 2
1989 3
1990 2
1992 2
1993 3
1994 2
1995 8
1996 7
1997 3
1998 5
1999 8
2000 12
2001 12
2002 11
2003 22
2004 14
2005 18
2006 25
2007 18
2008 31
2009 24
2010 31
2011 40
2012 43
2013 43
2014 49
2015 57
2016 57
2017 65
2018 104
2019 120
2020 114
2021 157
2022 116
2023 119
2024 77

Text availability

Article attribute

Article type

Publication date

Search Results

1,300 results

Results by year

Filters applied: . Clear all
Page 1
Immune checkpoint therapy-current perspectives and future directions.
Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, Liu J, Subudhi SK, Poon C, Gant KL, Herbrich SM, Anandhan S, Islam S, Amit M, Anandappa G, Allison JP. Sharma P, et al. Cell. 2023 Apr 13;186(8):1652-1669. doi: 10.1016/j.cell.2023.03.006. Cell. 2023. PMID: 37059068 Free article. Review.
Immune checkpoint therapy (ICT) has dramatically altered clinical outcomes for cancer patients and conferred durable clinical benefits, including cure in a subset of patients. Varying response rates across tumor types and the need for predictive biomarkers to optimi …
Immune checkpoint therapy (ICT) has dramatically altered clinical outcomes for cancer patients and conferred durable clinical …
Immunotherapy: Reshape the Tumor Immune Microenvironment.
Lv B, Wang Y, Ma D, Cheng W, Liu J, Yong T, Chen H, Wang C. Lv B, et al. Front Immunol. 2022 Jul 6;13:844142. doi: 10.3389/fimmu.2022.844142. eCollection 2022. Front Immunol. 2022. PMID: 35874717 Free PMC article. Review.
The interactions between these components, which are divided into anti-tumor and pro-tumor, determine the trend of anti-tumor immunity. Although the immune system can eliminate tumor through the cancer-immune cycle, tumors appear to eventually evade from immune surv …
The interactions between these components, which are divided into anti-tumor and pro-tumor, determine the trend of anti-tumor immu …
Progress in research on paclitaxel and tumor immunotherapy.
Zhu L, Chen L. Zhu L, et al. Cell Mol Biol Lett. 2019 Jun 13;24:40. doi: 10.1186/s11658-019-0164-y. eCollection 2019. Cell Mol Biol Lett. 2019. PMID: 31223315 Free PMC article. Review.
With the advancement of biotechnology, improvements in endophytic fungal strains, and the use of recombination techniques and microbial fermentation engineering, the yield of extracted paclitaxel has increased significantly. Recently, paclitaxel has been found to play a large rol …
With the advancement of biotechnology, improvements in endophytic fungal strains, and the use of recombination techniques and microbial ferm …
Bispecific dendritic-T cell engager potentiates anti-tumor immunity.
Shapir Itai Y, Barboy O, Salomon R, Bercovich A, Xie K, Winter E, Shami T, Porat Z, Erez N, Tanay A, Amit I, Dahan R. Shapir Itai Y, et al. Cell. 2024 Jan 18;187(2):375-389.e18. doi: 10.1016/j.cell.2023.12.011. Cell. 2024. PMID: 38242085
Immune checkpoint inhibition treatment using aPD-1 monoclonal antibodies is a promising cancer immunotherapy approach. However, its effect on tumor immunity is narrow, as most patients do not respond to the treatment or suffer from recurrence. ...By bridging immune …
Immune checkpoint inhibition treatment using aPD-1 monoclonal antibodies is a promising cancer immunotherapy approach. However, its effect o …
Fibrosis and cancer: A strained relationship.
Piersma B, Hayward MK, Weaver VM. Piersma B, et al. Biochim Biophys Acta Rev Cancer. 2020 Apr;1873(2):188356. doi: 10.1016/j.bbcan.2020.188356. Epub 2020 Mar 5. Biochim Biophys Acta Rev Cancer. 2020. PMID: 32147542 Free PMC article. Review.
A stiff ECM also induces angiogenesis, hypoxia and compromises anti-tumor immunity. Not surprisingly, tumor aggression and poor patient prognosis correlate with degree of tissue fibrosis and level of stromal stiffness. ...
A stiff ECM also induces angiogenesis, hypoxia and compromises anti-tumor immunity. Not surprisingly, tumor aggression and poo …
Type I interferon-mediated tumor immunity and its role in immunotherapy.
Yu R, Zhu B, Chen D. Yu R, et al. Cell Mol Life Sci. 2022 Mar 16;79(3):191. doi: 10.1007/s00018-022-04219-z. Cell Mol Life Sci. 2022. PMID: 35292881 Free PMC article. Review.
Immune checkpoint blockade (ICB) therapies have achieved remarkable clinical responses in patients with many different types of cancer; however, most patients who receive ICB monotherapy fail to achieve long-term responses, and some tumors become immunotherapy-resistant an …
Immune checkpoint blockade (ICB) therapies have achieved remarkable clinical responses in patients with many different types of cance …
Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy.
Luoma AM, Suo S, Wang Y, Gunasti L, Porter CBM, Nabilsi N, Tadros J, Ferretti AP, Liao S, Gurer C, Chen YH, Criscitiello S, Ricker CA, Dionne D, Rozenblatt-Rosen O, Uppaluri R, Haddad RI, Ashenberg O, Regev A, Van Allen EM, MacBeath G, Schoenfeld JD, Wucherpfennig KW. Luoma AM, et al. Cell. 2022 Aug 4;185(16):2918-2935.e29. doi: 10.1016/j.cell.2022.06.018. Epub 2022 Jul 7. Cell. 2022. PMID: 35803260 Free PMC article.
Neoadjuvant immune checkpoint blockade has shown promising clinical activity. Here, we characterized early kinetics in tumor-infiltrating and circulating immune cells in oral cancer patients treated with neoadjuvant anti-PD-1 or anti-PD-1/CTLA-4 in a clinical tri …
Neoadjuvant immune checkpoint blockade has shown promising clinical activity. Here, we characterized early kinetics in tumor-infiltra …
Vaccine Therapies for Cancer: Then and Now.
Morse MA, Gwin WR 3rd, Mitchell DA. Morse MA, et al. Target Oncol. 2021 Mar;16(2):121-152. doi: 10.1007/s11523-020-00788-w. Epub 2021 Jan 29. Target Oncol. 2021. PMID: 33512679 Free PMC article. Review.
It is now understood that many previous clinical trials of cancer vaccines used target antigens or vaccine designs that inherently lacked sufficient immunogenicity to induce clinical responses. ...Results from randomized, phase 3 studies testing therapeutic c …
It is now understood that many previous clinical trials of cancer vaccines used target antigens or vaccine designs that inherently la …
Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy.
Topalian SL, Forde PM, Emens LA, Yarchoan M, Smith KN, Pardoll DM. Topalian SL, et al. Cancer Cell. 2023 Sep 11;41(9):1551-1566. doi: 10.1016/j.ccell.2023.07.011. Epub 2023 Aug 17. Cancer Cell. 2023. PMID: 37595586 Review.
However, recent scientific evidence outlined here suggests that neoadjuvant immunotherapy can expand and transcriptionally modify tumor-specific T cell clones to enhance both intratumoral and systemic anti-tumor immunity. It further offers a unique "window of opport …
However, recent scientific evidence outlined here suggests that neoadjuvant immunotherapy can expand and transcriptionally modify tumor-spec …
Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity.
Gauthier L, Morel A, Anceriz N, Rossi B, Blanchard-Alvarez A, Grondin G, Trichard S, Cesari C, Sapet M, Bosco F, Rispaud-Blanc H, Guillot F, Cornen S, Roussel A, Amigues B, Habif G, Caraguel F, Arrufat S, Remark R, Romagné F, Morel Y, Narni-Mancinelli E, Vivier E. Gauthier L, et al. Cell. 2019 Jun 13;177(7):1701-1713.e16. doi: 10.1016/j.cell.2019.04.041. Epub 2019 May 30. Cell. 2019. PMID: 31155232 Free article. Review.
Over the last decade, various new therapies have been developed to promote anti-tumor immunity. Despite interesting clinical results in hematological malignancies, the development of bispecific killer-cell-engager antibody formats directed against tumor cells …
Over the last decade, various new therapies have been developed to promote anti-tumor immunity. Despite interesting clinica …
1,300 results